Commentary on Aristotle study (Apixaban compared with warfarin in patients with atrial fibrillation)

Abstract

One of important statements on the European Cardiology Congress 2011 in Paris was presentation of results of the Aristotle study. This is another important study demonstrating the benefits of one of the new anticoagulants - Factor Xa inhibitor apixaban.